The FDA has approved an Alzheimer’s drug that slowed the rate of cognitive decline in clinical trials without using an advisory committee. The high drug cost — priced at $26,000 per year, Eisai said — combined with strict restrictions on reimbursement by US government-funded health schemes will severely limit the number of patients able to access the medicine, at least for now. What is going on here?